Patents Assigned to NovelMed Therapeutics, Inc.
-
Patent number: 10858420Abstract: A method of treating a hemolytic disorder in a subject in need thereof includes administering to the subject a therapeutically effective amount of an antibody that binds to a component of alternative pathway C3 convertase and selectively inhibits C3a, C5a, C3b, C5b, and C5b-9 produced exclusively by the alternative pathway, without inhibiting any of the classical pathway's ability to produce C3a, C5a, C3b, C5b, and C5b-9.Type: GrantFiled: June 5, 2018Date of Patent: December 8, 2020Assignee: NOVELMED THERAPEUTICS, INC.Inventor: Rekha Bansal
-
Patent number: 10711056Abstract: The invention is a method for reducing the effector functions of a therapeutic neutralizing antibody by administering to the afflicted subject an effective amount of an engineered aglycosylated human monoclonal antibody containing an engineered Fc region, wherein aglycosylation of the Fc region prevents therapeutic antibody-mediated cell activation, inflammation, C1q binding to the antibody and antibody triggered classical pathway activation.Type: GrantFiled: December 28, 2012Date of Patent: July 14, 2020Assignee: NOVELMED THERAPEUTICS, INC.Inventor: Rekha Bansal
-
Patent number: 10696740Abstract: A method of treating a complement mediated ocular inflammation, hemorrhaging and fibrosis, and the pathological consequences thereof, in a subject in need thereof, the method comprising of administering to the subject a therapeutically effective amount of an antibody which inhibits the alternative complement pathway, wherein the antibody administered is effective for inhibiting complement mediated ocular inflammation, hemorrhaging and fibrosis, and the pathological consequences thereof.Type: GrantFiled: January 22, 2019Date of Patent: June 30, 2020Assignee: NOVELMED THERAPEUTICS, INC.Inventor: Rekha Bansal
-
Patent number: 10183989Abstract: A method of treating a complement mediated ocular inflammation, hemorrhaging and fibrosis, and the pathological consequences thereof, in a subject in need thereof, the method comprising of administering to the subject a therapeutically effective amount of an antibody which inhibits the alternative complement pathway, wherein the antibody administered is effective for inhibiting complement mediated ocular inflammation, hemorrhaging and fibrosis, and the pathological consequences thereof.Type: GrantFiled: August 6, 2014Date of Patent: January 22, 2019Assignee: Novelmed Therapeutics, Inc.Inventor: Rekha Bansal
-
Patent number: 10131706Abstract: A pharmaceutical composition includes an isolated anti-Bb antibody or antigen binding portion thereof produced by a hybridoma cell line deposited under ATCC Accession Number PTA-8543 or an isolated anti-Bb antibody or antigen binding portion thereof that competitively inhibits binding of the antibody or antigen binding portion produced by the hybridoma cell line deposited under ATCC Accession Number PTA-8543 to the Bb segment of factor B; and a pharmaceutically acceptable carrier.Type: GrantFiled: March 16, 2015Date of Patent: November 20, 2018Assignee: NOVELMED THERAPEUTICS, INC.Inventor: Rekha Bansal
-
Patent number: 9988441Abstract: A method of treating a hemolytic disorder in a subject in need thereof includes administering to the subject a therapeutically effective amount of an antibody that binds to a component of alternative pathway C3 convertase and selectively inhibits C3a, C5a, C3b, C5b, and C5b-9 produced exclusively by the alternative pathway, without inhibiting any of the classical pathway's ability to produce C3a, C5a, C3b, C5b, and C5b-9.Type: GrantFiled: April 6, 2015Date of Patent: June 5, 2018Assignee: Novelmed Therapeutics, Inc.Inventor: Rekha Bansal
-
Patent number: 9926366Abstract: A method of treating a hemolytic disorder in a subject in need thereof includes administering to the subject a therapeutically effective amount of an antibody that binds to a component of alternative pathway C3 convertase and selectively inhibits C3a, C5a, C3b, C5b, and C5b-9 produced exclusively by the alternative pathway, without inhibiting any of the classical pathway's ability to produce C3a, C5a, C3b, C5b, and C5b-9.Type: GrantFiled: October 4, 2013Date of Patent: March 27, 2018Assignee: NOVELMED THERAPEUTICS, INC.Inventor: Rekha Bansal
-
Patent number: 9816999Abstract: A method for diagnosing the development of a tissue injury in a subject comprising administering a sample of neoantibodies to the subject's tissue for the purpose of detecting the presence of neoepitopes bearing complement proteins.Type: GrantFiled: January 26, 2015Date of Patent: November 14, 2017Assignee: Novelmed Therapeutics, Inc.Inventor: Rekha Bansal
-
Patent number: 9676842Abstract: A method of inhibiting alternative complement pathway activation in a mammal includes administering an amount of an antibody and/or fragment thereof that specifically binds to an epitope of the N terminus end of properdin effective to the inhibit alternative complement pathway in the subject.Type: GrantFiled: June 11, 2014Date of Patent: June 13, 2017Assignee: NOVELMED THERAPEUTICS, INC.Inventor: Rekha Bansal
-
Patent number: 9566297Abstract: The present invention provides compositions and methods to inhibit fibrosis and scarring associated with surgery. The present invention relates to the discovery that a synthetic anionic polymer consisting of dextran-sulfate (anionic carbohydrate) conjugated to Tirofiban (an anti-platelet agent which prevents platelet activation and aggregation) can effectively inhibit adhesions that form during surgery. This application is a continuation in part to U.S. patent application Ser. No. 13/202,006. The novel biocompatible conjugate compound of the original application can effectively inhibit fibrosis, scar formation, and surgical adhesions. The invention is predicated on the discovery that the conjugate compound effectively inhibits the invasion of cells which is associated with detrimental healing processes without affecting platelet populations. Use of any of several different anionic components with any of several different anti-platelet agents results in many different specific embodiments of the invention.Type: GrantFiled: March 24, 2014Date of Patent: February 14, 2017Assignee: Novelmed Therapeutics, Inc.Inventor: Rekha Bansal
-
Patent number: 9243060Abstract: A method of inhibiting complement activation mediated by C3b inhibitors in a subject includes administering a C3b inhibitor to the subject to inhibit at least one of C3b binding to factors B and properdin, inhibit C3 cleavage, inhibit the activation of neutrophils, monocytes, platelets, and endothelium; or inhibit the formation of C3a, C5a, and MAC.Type: GrantFiled: April 2, 2013Date of Patent: January 26, 2016Assignee: Novelmed Therapeutics, Inc.Inventor: Rekha Bansal
-
Patent number: 9243070Abstract: A method of inhibiting complement activation mediated by Bb inhibitors in a subject includes administering a Bb inhibitor to the subject to inhibit at least one of Bb binding to factors B and properdin, inhibit C3 cleavage, inhibit the activation of neutrophils, monocytes, platelets, and endothelium; or inhibit the formation of C3a, C5a, and MAC.Type: GrantFiled: April 2, 2013Date of Patent: January 26, 2016Assignee: Novelmed Therapeutics, Inc.Inventor: Rekha Bansal
-
Patent number: 9040507Abstract: A method for treating an autoimmune disease in a subject includes administering to the subject a therapeutically effective amount of an agent comprising an imidazole, an estrogen receptor agonist, or pharmaceutically acceptable salts thereof.Type: GrantFiled: June 2, 2009Date of Patent: May 26, 2015Assignee: Novelmed Therapeutics, Inc.Inventor: Rekha Bansal
-
Patent number: 9023831Abstract: A method of inhibiting the adverse effects of complement pathway, activation products in a subject comprising administering to the subject an amount of Dextran Sulfate effective to inhibit formation of alternative complement pathway activation product.Type: GrantFiled: April 24, 2008Date of Patent: May 5, 2015Assignee: Novelmed Therapeutics, Inc.Inventor: Rekha Bansal
-
Publication number: 20150064202Abstract: A method of inhibiting complement activation mediated by C3b inhibitors in a subject includes administering a C3b inhibitor to the subject to inhibit at least one of C3b binding to factors B and properdin, inhibit C3 cleavage, inhibit the activation of neutrophils, monocytes, platelets, and endothelium; or inhibit the formation of C3a, C5a, and MAC.Type: ApplicationFiled: April 2, 2013Publication date: March 5, 2015Applicant: NovelMed Therapeutics, Inc.Inventor: Rekha Bansal
-
Patent number: 8940490Abstract: A method for diagnosing the development of a tissue injury in a subject comprising administering a sample of neoantibodies to the subject's tissue for the purpose of detecting the presence of neoepitopes bearing complement proteins.Type: GrantFiled: November 29, 2011Date of Patent: January 27, 2015Assignee: Novelmed Therapeutics, Inc.Inventor: Rekha Bansal
-
Publication number: 20140127204Abstract: A method of inhibiting alternative complement pathway activation in a mammal includes administering an amount of an antibody and/or fragment thereof that specifically binds to an epitope of the N terminus end of properdin effective to the inhibit alternative complement pathway in the subject.Type: ApplicationFiled: March 22, 2013Publication date: May 8, 2014Applicant: NovelMed Therapeutics, Inc.Inventor: NovelMed Therapeutics, Inc.
-
Patent number: 8680075Abstract: A method for inhibiting cellular proliferation of fibroblasts and/or glioma cells in a mammal includes administering a composition to a mammal wherein the composition includes an amount of an anionic polymer and an anti-platelet agent effective to inhibit cellular proliferation of fibroblasts and gliomas in the mammal.Type: GrantFiled: February 17, 2010Date of Patent: March 25, 2014Assignee: Novelmed Therapeutics, Inc.Inventor: Rekha Bansal
-
Publication number: 20140056808Abstract: A method for diagnosing the development of a tissue injury in a subject comprising administering a sample of neoantibodies to the subject's tissue for the purpose of detecting the presence of neoepitopes bearing complement proteins.Type: ApplicationFiled: November 29, 2011Publication date: February 27, 2014Applicant: NovelMed Therapeutics, Inc.Inventor: Rekha Bansal
-
Patent number: 8435512Abstract: A method of inhibiting alternative complement pathway activation in a mammal includes administering an amount of an antibody and/or fragment thereof that specifically binds to an epitope of the N terminus end of properdin effective to the inhibit alternative complement pathway in the subject.Type: GrantFiled: June 27, 2008Date of Patent: May 7, 2013Assignee: Novelmed Therapeutics, Inc.Inventor: Rekha Bansal